Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Molecular targets for AIDS therapy.

H Mitsuya1, R Yarchoan, S Broder

  • 1National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.

Science (New York, N.Y.)
|September 28, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PU.1 acts as tumor suppressor for myeloma cells through direct transcriptional repression of IRF4.

Oncogene·2017
Same author

Molecular and cellular analyses of HLA class II-associated susceptibility to autoimmune diseases in the Japanese population.

Modern rheumatology·2014
Same author

PDK1 inhibition is a novel therapeutic target in multiple myeloma.

British journal of cancer·2013
Same author

Effect of translocation defective reverse transcriptase inhibitors on the activity of N348I, a connection subdomain drug resistant HIV-1 reverse transcriptase mutant.

Cellular and molecular biology (Noisy-le-Grand, France)·2013
Same author

The sugar ring conformation of 4'-ethynyl-2-fluoro-2'-deoxyadenosine and its recognition by the polymerase active site of HIV reverse transcriptase.

Cellular and molecular biology (Noisy-le-Grand, France)·2011
Same author

PU.1 induces apoptosis in myeloma cells through direct transactivation of TRAIL.

Oncogene·2009
Same journal

Erratum for the Research Article "Detecting supramolecular organic nanoparticles during heat wave".

Science (New York, N.Y.)·2026
Same journal

Local signals, systemic decline.

Science (New York, N.Y.)·2026
Same journal

The mechanics of liver regeneration.

Science (New York, N.Y.)·2026
Same journal

Computing in a memory with physics.

Science (New York, N.Y.)·2026
Same journal

Retraction.

Science (New York, N.Y.)·2026
Same journal

Making time.

Science (New York, N.Y.)·2026
See all related articles

Antiretroviral therapy, including nucleoside analogs like AZT, inhibits HIV replication. Future AIDS treatments will likely focus on non-nucleoside drugs to combat HIV morbidity and mortality.

Area of Science:

  • Virology
  • Pharmacology
  • Immunology

Background:

  • Acquired immunodeficiency syndrome (AIDS) research intensifies following human immunodeficiency virus (HIV) discovery.
  • Antiretroviral therapies aim to inhibit HIV replication through various drug classes.
  • Nucleoside analogs, like 3'-Azido-2',3'-dideoxythymidine (AZT), are key in inhibiting HIV reverse transcriptase.

Purpose of the Study:

  • To review the development of antiretroviral therapy for AIDS.
  • To highlight the role of nucleoside analogs in HIV treatment.
  • To discuss future directions in experimental AIDS therapy.

Main Methods:

  • Review of existing literature on antiretroviral drugs and HIV replication.
  • Analysis of structure-activity relationships for nucleoside analogs.

Related Experiment Videos

  • Exploration of potential therapeutic targets in the HIV replication cycle.

    • Main Results:

    • A wide range of drugs inhibit HIV replication in vitro.
    • Nucleoside analogs require phosphorylation to inhibit reverse transcriptase.
    • AZT was the first dideoxynucleoside tested in AIDS patients, yielding significant structure-activity data.

    Conclusions:

    • HIV replication offers multiple targets for therapeutic intervention.
    • Non-nucleoside drugs are expected to play a larger role in future AIDS therapy.
    • Antiretroviral therapy will significantly impact HIV-related illness and death.